Halozyme Therapeutics (NASDAQ:HALO) Reaches New 12-Month High – Time to Buy?

Posted by George Bondi on Aug 18th, 2026

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) hit a new 52-week high on Tuesday . The company traded as high as $104.96 and last traded at $104.8050, with a volume of 848025 shares changing hands. The stock had previously closed at $103.00.

Analyst Ratings Changes

A number of analysts have recently commented on the company. UBS Group reissued a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Morgan Stanley reduced their price objective on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. HC Wainwright increased their target price on Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Finally, TD Cowen raised their price target on Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a report on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $91.20.

Get Our Latest Research Report on HALO

Halozyme Therapeutics Stock Performance

The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The stock has a market capitalization of $11.92 billion, a P/E ratio of 31.35, a P/E/G ratio of 0.40 and a beta of 0.85. The business has a fifty day moving average price of $80.30 and a 200-day moving average price of $72.79.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.Halozyme Therapeutics’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same period last year, the company earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current year.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $67.58, for a total transaction of $1,351,600.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $51,886,572.40. The trade was a 2.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the transaction, the director directly owned 40,418 shares in the company, valued at $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 44,103 shares of company stock worth $3,142,896 over the last quarter. Company insiders own 2.50% of the company’s stock.

Institutional Trading of Halozyme Therapeutics

A number of hedge funds have recently bought and sold shares of the company. MidFirst Bank bought a new position in Halozyme Therapeutics in the second quarter valued at about $27,000. Larson Financial Group LLC grew its stake in shares of Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 343 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Halozyme Therapeutics during the 2nd quarter valued at about $28,000. Measured Wealth Private Client Group LLC increased its position in shares of Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 124 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $30,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

(Get Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.